Wollschlaeger BA, Willson TM, Montejano LB, Ronquest NA, Nadipelli VR. Characteristics and treatment patterns of US commercially insured and Medicaid patients with opioid dependence or abuse. J Opioid Manag. 2017 Jul;13(4):207-20. doi: 10.5055/jom.2017.0389
Ronquest N, Wollschlaeger B, Montejano L, Wilson T, Nadipelli V. Characteristics and treatment patterns of US medicaid patients with opioid use disorder. Poster presented at the 2016 International Conference on Opioids Conference; June 2016. Boston, MA. [abstract] J Opioid Manag. 2016 May; 12(3):227.
Sawant RV, Goyal RK, Rajan SS, Essien EJ, Patel HK, Sansgiry SS. Factors associated with intention to engage in self-protective behavior: the case of over-the-counter acetaminophen products. Res Social Adm Pharm. 2016 Mar;12(2):327-35. doi: 10.1016/j.sapharm.2015.06.005
Lucas AM, Armbruster B. The cost-effectiveness of expanded HIV screening in the United States. AIDS. 2013 Mar 13;27(5):795-801. doi: 10.1097/QAD.0b013e32835c54f9
Mauskopf J, Brogan AJ, Talbird SE, Martin S. Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection. AIDS. 2012 Jan 1;26(3):355-64.
Hauber AB, Fleischmann J, Lothgren M, Wilson M, Lam A, Dubois D, Sabatowski R. Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective. J Opioid Manag. 2011 Jul 1;7(4):287-96.
Pipkin S, Scheer S, Okeigwe I, Schwarcz S, Harris DH, Hessol NA. The effect of HAART and calendar period on Kaposi's sarcoma and non-Hodgkin lymphoma: results of a match between an AIDS and cancer registry. AIDS. 2011 Feb 20;25(4):463-71.
Nagar S, Mehta S, Bhatara V, Aparasu R. Health care consequences of black-box warnings for antidepressants in the United States and Canada. Res Social Adm Pharm. 2010 Mar;6(1):78-84.
Doward LC, Dietz B, Wilburn J, McKenna SP, Bhor M, Rajagopalan R. Impact of lipoatrophy on patient-reported outcomes in ART-experienced patients. AIDS. 2008 May 1;20(10):1197-201.